TERAZOSIN HYDROCHLORIDE capsule

দেশ: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

TERAZOSIN HYDROCHLORIDE (UNII: D32S14F082) (TERAZOSIN - UNII:8L5014XET7)

থেকে পাওয়া:

Quality Care Products LLC

INN (আন্তর্জাতিক নাম):

TERAZOSIN HYDROCHLORIDE

রচনা:

TERAZOSIN 5 mg

প্রশাসন রুট:

ORAL

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

Terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin hydrochloride. The long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin hydrochloride is also indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. Terazosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

পণ্য সারাংশ:

Terazosin Hydrochloride Capsules, 2 mg, 5 mg contain 2 mg, or 5 mg terazosin as terazosin hydrochloride anhydrous, respectively. They are supplied by State of Florida DOH Central Pharmacy as follows: Store at 15° to 30°C (59° to 86°F). [See USP for Controlled Room Temperature.] Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. PHARMACIST: Dispense Patient Information Leaflet with each prescription.

অনুমোদন অবস্থা:

Abbreviated New Drug Application

পণ্য বৈশিষ্ট্য

TERAZOSIN HYDROCHLORIDE- TERAZOSIN HYDROCHLORIDE CAPSULE
QUALITY CARE PRODUCTS LLC
----------
TERAZOSIN HYDROCHLORIDE CAPSULES
1 MG, 2 MG, 5 MG AND 10 MG
RX ONLY
1
DESCRIPTION
Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking
agent, is a
quinazoline derivative represented by the following structural
formula, molecular formula
and chemical name:
Piperazine,
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetra-hydro-2-
furanyl)carbonyl]-, monohydrochloride, anhydrous.
Terazosin hydrochloride is a white, crystalline substance, freely
soluble in water and
isotonic saline and has a molecular weight of 459.93. Each terazosin
hydrochloride
capsule, for oral administration, contains 1 mg, 2 mg, 5 mg or 10 mg
of terazosin as
terazosin hydrochloride anhydrous. Each capsule contains the following
inactive
ingredients: crospovidone, lactose (monohydrate), magnesium stearate
and
microcrystalline cellulose. The capsule shells and imprinting inks
contain: D & C Yellow #
10 Aluminum Lake, FD & C Blue # 1 Aluminum Lake, FD & C Blue # 2
Aluminum Lake, FD
& C Red # 40 Aluminum Lake, gelatine, pharmaceutical glaze, propylene
glycol, silicon
dioxide, sodium lauryl sulfate, synthetic black iron oxide, and
titanium dioxide. The 5 mg
also contains; D & C Red # 28.
CLINICAL PHARMACOLOGY
PHARMACODYNAMICS
BENIGN PROSTATIC HYPERPLASIA (BPH)
The symptoms associated with BPH are related to bladder outlet
obstruction, which is
1
(_EACH CAPSULE CONTAINS 1 MG, 2 MG, 5 MG OR 10 MG OF TERAZOSIN AS
TERAZOSIN_
_HYDROCHLORIDE ANHYDROUS_)
comprised of two underlying components: a static component and a
dynamic
component. The static component is a consequence of an increase in
prostate size.
Over time, the prostate will continue to enlarge. However, clinical
studies have
demonstrated that the size of the prostate does not correlate with the
severity of BPH
symptoms or the degree of urinary obstruction. The dynamic component
is a function
of an increase in smooth muscle tone in the prostate and bladder neck,
leading to
constriction of th